Metabolic, Vascular and Therapeutic Aspects of Lipoprotein(a)

Qidi Ying

Research output: ThesisDoctoral Thesis

129 Downloads (Pure)


Lipoprotein(a) [Lp(a)] is a causal risk factor of atherosclerotic cardiovascular disease (ASCVD). Clinical interventions using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or high dose omega-3 fatty acids (ω-3FAs) may have an impact on Lp(a) metabolism and associated cardiovascular sequelae. Five studies were carried out to investigate the metabolic, vascular and therapeutic aspects of Lp(a). The results of these studies collectively support the overall hypothesis of the thesis that the metabolism of Lp(a) and associated cardiovascular sequelae are modifiable by clinical interventions in human subjects.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
  • Pang, Jing, Supervisor
  • Chan, Dick, Supervisor
  • Watts, Gerald, Supervisor
Thesis sponsors
Award date8 Jun 2023
Publication statusUnpublished - 2023


Dive into the research topics of 'Metabolic, Vascular and Therapeutic Aspects of Lipoprotein(a)'. Together they form a unique fingerprint.

Cite this